-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 23rd GemVax released more positive data for the GV1001 Alzheimer's II trial at the Korean Association for Theaset of Mental Disorders' autumn meeting.
, the company has announced that the GV1001 has good tolerance and safety, and achieved the main endpoint by making significant improvements in the SIB score.
latest data also show significant improvements in neuropsynamic scale (NPI) statistics, as well as improvements in the daily energy scale (ADCS-ADL) score for collaborative Alzheimer's research.
these results, the company now plans to submit three IND applications.
GemVax's GV1001 Drug Phase II clinical trial assessed the safety and effectiveness of 0.56 ml or 1.12 ml of GV1001 sepsis injections in patients with moderate to severe Alzheimer's disease who had been treated with Donai pyridox for more than three months in 12 medical institutions over a six-month period.
note: There are deletions in the original text